Marché indien de la synthèse des oligonucléotides – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché indien de la synthèse des oligonucléotides

Le marché indien de la synthèse d'oligonucléotides devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs du marché et de la disponibilité de dispositifs technologiques avancés. Le développement croissant dans le domaine des techniques avancées devrait en outre stimuler la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation des produits devraient freiner la croissance du marché au cours de la période de prévision.

Data Bridge Market Research analyse que le marché indien de la synthèse d'oligonucléotides devrait atteindre la valeur de 191,35 millions USD d'ici 2030, à un TCAC de 7,4 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.

Définition du marché

Oligonucleotides can be formed either enzymatically through the cleavage of larger biomolecules or targeted chemical synthesis. In the latter case, organonucleotide synthesis is the chemical process by which nucleoside phosphoramidites – a key monomeric element of oligonucleotides – are synthesized. Nucleoside phosphoramidites (also known as nucleosides or amidites) themselves are derivatives of natural or synthetic nucleosides. Oligonucleotide synthesis is the chemical process by which nucleotides are specifically linked to form the desired sequenced product. Continuous solid phase synthesis using a packed-bed column is commonly used for producing oligonucleotides. In some cases, a batch, slurry reaction is employed.

India Oligonucleotides Synthesis market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Use of Synthesized Oligonucleotides in Various Applications

Many technologies have been developed to improve oligonucleotide pharmacokinetics and pharmacodynamics. The field of oligonucleotides synthesis has seen significant advancements in recent years with the advent of oligos. With diversifying applications, India oligonucleotides synthesis market presents a significant opportunity for growth. The massive and cheap oligos produced by large-scale oligo synthesis can be used for many purposes, enabling numerous interesting applications. For example, the oligos can be used for the constructions of large cell populations or DNA variations, which are beneficial in engineering regulatory elements, genetic networks, metabolic pathways, and DNA origami.

Oligonucleotides synthesis allows performing precise and targeted procedures without the need for traditional methods. For most applications, very small quantities of DNA are required, and oligonucleotide synthesis is performed mainly on the 40 nmol scale or lower. This provides ample quantities for most biochemical and biological experiments. Much larger amounts of DNA 10 µmol or more can be prepared for use in biophysical studies nuclear magnetic resonance and X-ray crystallography.

Thus, the use of synthesized oligonucleotides in various applications is expected to present significant growth in the India oligonucleotides synthesis market.

• Increasing Government Investments and R&D Expenditure

The benefits of oligonucleotides synthesis can lead to increased demand for various testing methods. The advantages of quick results, reduced turnaround times, and improved patient care, there is a greater likelihood of healthcare providers incorporating oligonucleotides synthesis into their practices. This increased demand can drive the growth of the oligonucleotides synthesis market. The government, federations, and major players in the market are involved in spreading awareness among society across developing countries. These initiatives by the players and government are helping the users to reach out and take advantage of the policies made for low-income and developing nations. The growth of oligonucleotides synthesis in pharmaceutical companies and forensic labs is already strongly encouraged by government initiatives and the prevalence of time-sensitive medical diseases.

Thus, these steps by the federations, associations, and healthy trending laboratories including the government are involved in spreading awareness and also helping the newly established authorities to take structural decisions for improving diagnostics and research. Thus, the increasing Government Investments and R&D Expenditure are expected to drive market growth.

Opportunity

 Rising Technological Advancements

To address the constantly changing needs of many industries, technological breakthroughs in Oligonucleotides synthesis are giving considerable increases in their performance, durability, and versatility. These developments are changing the way surface protection is practiced, providing users with better security and ease.

The substantial rise in technological advancements in India presents a significant opportunity for growth within the Oligonucleotides synthesis market. Oligonucleotides synthesis stands out as a pivotal tool for advancing precision medicine and personalized treatments as the country allocates increasing resources to enhance its healthcare infrastructure and address a range of medical challenges. The heightened investment in healthcare translates into greater demand for innovative solutions that can effectively tackle complex diseases, including genetic and chronic conditions.

Overall, the business has undergone a revolution thanks to recent technological developments in Oligonucleotides synthesis. Rising technological advancements is also beneficial for further economic growth and healthcare sector growth, and it is primarily fruitful as it significantly affects the development of better and more advanced medical products in the market. Thereby, the surge in rising technological advancements is expected to create opportunities for market growth.

Restraint / Challenge

Limitation of Oligonucleotides Synthesis

Healthcare professionals rely on clinical evidence to make informed treatment decisions. Limited clinical evidence for oligonucleotides synthesis can lead to hesitancy among healthcare professionals in adopting these techniques. Without sufficient data demonstrating the safety, efficacy, and long-term outcomes of oligonucleotides synthesis, healthcare providers may be less inclined to offer or recommend these procedures to their patients.

Limited clinical evidence may impact rising acceptance and confidence in oligonucleotides synthesis. Patients often rely on evidence-based information to make decisions about their healthcare. Insufficient clinical evidence may lead to skepticism, making healthcare professionals less willing to consider oligonucleotides synthesis as a diagnostic, research, or treatment option. Limitation of oligonucleotides synthesis can hinder the market growth of oligonucleotides synthesis market.

Recent Developments

• In December 2022, Thermo Fisher Scientific, the world leader in serving science, announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases. TrueMark Infectious Disease Research Panels are analytically sensitive, syndromic panels for the analysis of a wide range of infectious disease pathogens. This will help the organization in developing overall revenue.
• In January 2021, Merck KGaA announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applications.
• In April 2019, Agilent Technologies, Inc. launched a new Mass Spectrometry solution Agilent 6546 LC/Q-TOF which is an advanced version of traditional spectroscopy. This will improve the analytical testing of food and also be used in metabolomics research with accurate result.
• In March 2018, DANAHER signed an agreement to acquire Integrated DNA Technologies (IDT) which is a provider of high-value consumables for genomics applications in molecular biology, qPCR synthetic biology, and molecular diagnostics. As a result, there will be an expansion in the genomic market which will increase its product portfolio and revenue.
• In April 2019, Agilent Technologies, Inc. launched a new Mass Spectrometry solution Agilent 6546 LC/Q-TOF which is the advanced version of traditional spectroscopy.

India Oligonucleotides Synthesis Market Scope

Le marché indien de la synthèse des oligonucléotides est segmenté en six segments notables en fonction du type, du type de produit, de la méthode de synthèse, de l'application, de l'utilisateur final et du canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance maigres dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.

Taper

• Oligos personnalisés
• Oligos prédéfinis

Sur la base du type, le marché est segmenté en oligos personnalisés et oligos prédéfinis.

Type de produit

• Équipements
• Réactifs, consommables et accessoires

Sur la base du type de produit, le marché est segmenté en équipements et réactifs, consommables et accessoires.

Méthode de synthèse

• Méthode de synthèse d'oligo-éléments en phase solide
• Méthode de synthèse d'oligo-éléments en phase liquide/enzymatique

Sur la base de la méthode de synthèse, le marché est segmenté en méthode de synthèse d'oligos en phase solide et méthode de synthèse d'oligos en phase liquide/enzymatique.

Application

• Diagnostic
• Thérapeutique
• Recherche
• Agriculture
• Nourriture
• Autres

Sur la base des applications, le marché est segmenté en diagnostic, thérapeutique, recherche, agriculture, alimentation et autres.

Utilisateur final

• Sociétés pharmaceutiques et biotechnologiques
• Centres de diagnostic
• Organisation de recherche sous contrat
• Instituts de recherche et d'enseignement
• Laboratoires médico-légaux

Sur la base de l'utilisateur final, le marché est segmenté en sociétés pharmaceutiques et biotechnologiques, laboratoires de diagnostic, organismes de recherche sous contrat, instituts de recherche et universitaires, laboratoires médico-légaux.

Canal de distribution

• Vente directe
• Ventes au détail
• Autres

Sur la base du canal de distribution, le marché est segmenté en ventes directes, ventes au détail et autres.

Paysage concurrentiel et analyse des parts de marché de la synthèse des oligonucléotides en Inde

Le paysage concurrentiel du marché indien de la synthèse des oligonucléotides fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence dans le pays, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Certains des principaux acteurs du marché opérant sur le marché indien de la synthèse d'oligonucléotides sont Thermo Fisher Scientific Inc (États-Unis), Agilent Technologies Inc (États-Unis), Merck KGaA (Allemagne), Danaher (États-Unis), LGC Limited (Royaume-Uni), Eurofins Genomics (Inde), GENERAL ELECTRIC (États-Unis), METTLER TOLEDO (Inde), TriLink BioTechnologies (États-Unis), Ajinomoto Bio-Pharma (Japon), entre autres.

SKU-70222